Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and organ failure

Critical Care Medicine

Volumn 31, Issue 3, 2003, Pages 718-728

  Abraham, Edward ^a   Naum, Chris ^b   Bandi, Venkata ^c   Gervich, Daniel ^d   Lowry, Stephen F ^e   Wunderink, Richard ^f   Schein, Roland M ^g   Macias, William ^h   Skerjanec, Simona ^h   Dmitrienko, Alex ^h   Farid, Nagy ^h   Forgue, S Thomas ^h   Jiang, Frank ^h  

^a UNIVERSITY OF COLORADO   (United States)

^b METHODIST HOSPITAL   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d Mercy West Clinic   (United States)

^e ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^f Methodist Hospital Central   (United States)

^g UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^h ELI LILLY AND COMPANY   (United States)

Author keywords

Group IIA secretory phospholipase; LY315920Na S 5920; Organ failure; Severe sepsis

Indexed keywords

PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 INHIBITOR; PLACEBO; UNCLASSIFIED DRUG; VARESPLADIB;

ABDOMINAL ENLARGEMENT; ABDOMINAL SWELLING; ACIDOSIS; ARTICLE; BLOOD CLOTTING DISORDER; CARDIOTOXICITY; CHOLELITHIASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENZYME INHIBITION; FEMALE; HEART ARREST; HEART ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HEMATURIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; PNEUMOTHORAX; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SURVIVAL;

ACETIC ACIDS; AGED; CAUSE OF DEATH; CRITICAL ILLNESS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG MONITORING; FEMALE; HOSPITAL MORTALITY; HUMANS; INDOLES; INFLAMMATION; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MOLECULAR WEIGHT; MULTIPLE ORGAN FAILURE; PHOSPHOLIPASES A; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; SAFETY; SURVIVAL ANALYSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 0037352612     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000053648.42884.89     Document Type: Article

References (38)

1. Angus DC, Linde-Zwirble WT, Lidicker J, et al: Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-1310
2. Bone RC, Fisher CJ Jr, Clemmer TP, et al: A controlled clinical trial of high-dose methyl-prednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987; 317:653-658
3. Bone RC, Fisher CJ Jr, Clemmer TP, et al: Sepsis syndrome: A valid clinical entity. Crit Care Med 1989; 17:389-393
4. Ziegler EJ, Fisher CJ, Sprung CL, et al: Treatment of gram negative bacteremia and septic shock with HA-1A human monoclonal anti-body against endotoxin: A randomized, double-blind placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med 1991; 324:429-436
5. Parrillo JE: Management of septic shock: Present and future. Ann Intern Med 1991; 115:491-493
6. Rangel-Frausto MS, Pittet D, Costigan M, et al: The natural history of the systemic inflammatory response syndrome (SIRS): A prospective study. JAMA 1995; 273:117-123
7. Sands KE, Bates DW, Lanken PN, et al: Epidemiology of sepsis syndrome in 8 academic medical centers. JAMA 1997; 278:234-240
8. Bernard GR, Vincent JL, Laterre PF, et al: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709
9. Parrillo JE, Parker MM, Natanson C, et al: Septic shock in humans. Ann Intern Med 1990; 113:227-242
10. Centers for Disease Control: Increase in national hospital discharge survey rates for septicemia: United States, 1979-1987. MMWR Morb Mortal Wkly Rep 1990; 39:31-34
11. Chaby R: Strategies for the control of LPS-mediated pathophysiological disorders. Drug Discov Today 1999; 4:209-221
12. Arrieta O, Rodriguez-Reyna TS, Sotelo J: Pharmacological treatment of septic shock. Expert Opinion Ther Patents 2000; 10:601-622
13. van der Poll T, Butler HR, ten Cate H, et al: Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 1990; 322:1622-1627
14. Abraham E, Wunderink R, Silverman H, et al: Efficacy and safety of monoclonal anti-body to human tumor necrosis factor alpha in patients with sepsis syndrome: A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA 1995; 273:934-941
15. Cohen J, Carlet J: INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med 1996; 24:1431-1440
16. Fisher CJ Jr, Dhainaut JF, Opal SM, et al: Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome: Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 1994; 271:1836-1843
17. Opal SM, Fisher CJ Jr, Dhainaut JF, et al: Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: A phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med 1997; 25:1115-1124
18. Bernard G, Artigas A, Dellinger P, et al: Clinical expert round table discussion (session 3) at the Margaux Conference on Critical Illness: The role of activated protein C in severe sepsis. Crit Care Med 2001; 29(Suppl 7):S75-S77
19. Edelson JD, Vadas P, Villar J, et al: Acute lung injury induced by phospholipase A2: Structural and functional changes. Am Rev Respir Dis 1991; 143:1102-1109
20. Wojtaszek PA, Van Putten V, Nemenoff RA: Activation of a novel form of phospholipase A2 during liver regeneration. FEBS Lett 1995; 367:228-232
21. Anderson BO, Moore EE, Banerjee A: Phospholipase A2 regulates critical inflammatory mediators of multiple organ failure. J Surg Res 1994; 56:199-205
22. Tramposch KM, Chilton FH, Stanley PL, et al: Inhibitor of phospholipase A2 blocks eicosanoid and platelet activating factor biosynthesis and has topical anti-inflammatory activity. J Pharmacol Exp Ther 1994; 271:852-859
23. Boermeester MA, van Leeuwen PA, Coyle SM, et al: Interleukin-1 blockade attenuates mediator release and dysregulation of the hemostatic mechanism during human sepsis. Arch Surg 1995; 130:739-748
24. Endo S, Inada K, Nakae H, et al: Plasma levels of type II phospholipase A2 and cytokines in patients with sepsis. Res Commun Mol Path Pharmacol 1995; 90:413-421
25. Guidet B, Piot O, Masliah J, et al: Secretory non-pancreatic phospholipase A2 in severe sepsis: Relation to endotoxin, cytokines and thromboxane B2. Infection 1996; 24:103-108
26. Vadas P, Pruzanski W, Stefanski E: Pathogenesis of hypotension in septic shock: Correlation of circulating phospholipase A2 levels with circulatory collapse. Crit Care Med 1988; 16:1-7
27. Buchler M, Deller A, Malfertheiner P, et al: Serum phospholipase A2 in intensive care patients with peritonitis, multiple injury, and necrotizing pancreatitis. Klin Wochenschr 1989; 67:217-221
28. Uhl W, Buchler M, Nevalainen TJ, et al: Serum phospholipase A2 in patients with multiple injuries. J Trauma 1990; 30:1285-1290
29. Vadas P, Stefanski E, Pruzanski W: Influence of plasma proteins on activity of proinflammatory enzyme phospholipase A2. Inflammation 1986; 10:183-193
30. 2. Presented at Inflammation Research Association 8th International Conference on Inflammation: Mechanisms and Therapeutics, October 27-31, 1996, Hershey, PA
31. Furue S, Mikawa K, Nishina K, et al: Therapeutic time-window of a group IIA phospholipase A2 inhibitor in rabbit acute lung injury: Correlation with lung surfactant protection. Crit Care Med 2001; 29:719-727
32. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. Bull World Health Organ 2001; 79:373-374
33. Knaus WA, Draper EA, Wagner DP, et al: APACHE II: A severity of disease classification system. Crit Care Med 1985; 13:818-829
34. Vincent JL, Moreno R, Takala J, et al: The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/ failure: On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996; 22:707-710
35. Katz S, Ford AB, Moskowitz RW, et al: Studies of illness in the aged: The index of ADL, a standardized measure of biological and psychosocial function. JAMA 1963; 185:914-919
36. Yang HC, Mosior M, Johnson CA, et al: Group-specific assays that distinguish between the four major types of mammalian phospholipase A2. Anal Biochem 1999; 269:278-288
37. Snyder DW, Bach NJ, Dillard RD, et al: Pharmacology of LY315920/S-5920, [[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy] acetate, a potent and selective secretory phospholipase A2 inhibitor: A new class of anti-inflammatory drugs, SPI. J Pharmacol Exp Ther 1999; 288:1117-1124
38. Abraham E, Glauser MP, Butler T, et al: p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock: A randomized controlled multicenter trial. Ro 45-2081 Study Group. JAMA 1997; 277: 1531-1538